# Title

 Food and Drugs. PART 346â€”ANORECTAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE


# ID

 CFR-2018-title21-vol5.Pt. 346


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                       |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['not to exceed', 'maximum', 'more than', 'before', 'after', 'minimum', 'less than', 'at least', 'within', 'exceed']                                                                                                                         |
| Duration    | ['12.0 year', '24.0 hour', '7.0 day']                                                                                                                                                                                                        |
| Condition   | ['subject to', 'provided that', 'when', 'if', 'unless']                                                                                                                                                                                      |
| Entities    | ['Temporarily', 'Can', 'Remove', 'Scope', 'Topical', 'Keratolytic', 'Directions', 'Apply', 'Local', 'Permitted', 'Calamine', 'Food', 'Witch', 'Indications', 'Certain', 'Children', 'Warnings', 'Vasoconstrictor', 'Lubricate', 'Analgesic'] |
| Date        | ['2018-05-12', '2018-05-16', '2018-05-18', '2018-05-20', '2018-05-10', '2018-01-20']                                                                                                                                                         |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                 |
|:--------------|:------------------------------------------------------------------------------------------------------------------------|
| within        | the following when used in the concentration or within the concentration range established for each ingredient: (a)     |
| within        | the following when used in the concentration or within  the concentration range established for each ingredient.        |
| less than     | active ingredients may be used in concentrations of less than 50 percent by weight only when used in                    |
| less than     | solution so that the final product contains not less than 10 and not more than 45 percent glycerin                      |
| more than     | product contains not less than 10 and not more than  45 percent glycerin (weight/weight).                               |
| at least      | Any combination product containing glycerin must contain  at least  this minimum amount of glycerin.                    |
| minimum       | product containing glycerin must contain at least this minimum  amount of glycerin.                                     |
| not to exceed | (o) and with the following limitations: (1) Calamine not to exceed 25 percent by weight per dosage unit (based          |
| not to exceed | (4) Zinc oxide  not to exceed  25 percent by weight per dosage unit.                                                    |
| within        | consists of any of the following when used within the concentration range established for each ingredient: (a)          |
| within        | consists of any of the following when used within the concentration range established for each ingredient: (a)          |
| within        | consists of any of the following when used within the concentration range established for each ingredient: (a)          |
| within        | (c) Zinc oxide,  within a concentration range of 5 to 25 percent                                                        |
| within        | consists of any of the following when used within the concentration range established for each ingredient: (a)          |
| at least      | weight of all protectants in the combination is at least 50 percent of the final product (e.g., 1                       |
| at least      | must be present at a level that contributes at least 12.5 percent by weight (e.g., 0.25 gram of                         |
| exceed        | is included in the combination, it must not exceed  the concentration limit specified in &#167;&#8201;346.14(b).        |
| within        | (1) &#8220;If condition worsens or does not improve within 7 days, consult a doctor.&#8221; (2) &#8220;Do not           |
| exceed        | 7 days, consult a doctor.&#8221; (2) &#8220;Do not exceed the recommended daily dosage unless directed by a             |
| before        | a doctor.&#8221; (ii) &#8220;Ask a doctor or pharmacist before use if you are [bullet]&#8201;1 presently taking a       |
| before        | &#8220;Remove petrolatum or greasy ointment  before using this product because they interfere with the                  |
| before        | blotting with toilet tissue or a soft cloth before application of this product.&#8221; [Other appropriate directions in |
| before        | &#8220;Remove wrapper  before inserting into the rectum.&#8221; (5) For products for                                    |
| after         | affected area up to 6 times daily or after  each bowel movement.                                                        |
| exceed        | the directions for the combination product may not exceed any maximum dosage limits established for the individual      |
| maximum       | for the combination product may not exceed any maximum dosage limits established for the individual ingredients in      |


## Duration

| Duration   | Context                                                                                                                                                                        |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24.0 hour  | (2) Cod liver oil, provided that the product is labeled so that the amount of the product that is used in a 24-hour period represents a quantity that provides 10,000 U.S.P.   |
| 24.0 hour  | (3) Shark liver oil, provided that the product is labeled so that the amount of the product that is used in a 24-hour period represents a quantity that provides 10,000 U.S.P. |
| 7.0 day    | The labeling of the product contains the following warnings under the heading &#8220;Warnings&#8221;:                                                                          |
|            |               (1) &#8220;If condition worsens or does not improve within 7 days, consult a doctor.&#8221;                                                                      |
|            |               (2) &#8220;Do not exceed the recommended daily dosage unless directed by a doctor.&#8221;                                                                        |
|            |               (3) &#8220;In case of bleeding, consult a doctor promptly.&#8221;                                                                                                |
|            |               (4) For products for external use only.                                                                                                                          |
| 12.0 year  | &#8220;Children under 12 years of age: consult a doctor.&#8221;                                                                                                                |
|            |               (2) For products for external use only.                                                                                                                          |


## Condition

| Condition     | Context                                                                                                                            |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| if            | as safe and effective and is not misbranded if it meets each condition in this part and                                            |
| unless        | Regulations are to chapter I of title 212 unless  otherwise noted.                                                                 |
| when          | irritation, and/or discomfort by reversibly blocking nerve conduction when  applied to nerve tissue in appropriate concentrations. |
| when          | the product consists of any of the following when used in the concentration or within the concentration                            |
| when          | the product consists of any of the following when used in the concentration or within the concentration                            |
| if            | the sole protectant active ingredient in a product if  the ingredient as ident                                                     |
| when          | of less than 50 percent by weight only when used in combinations in accordance with &#167;&#8201;346.22 (a),                       |
| provided that | (2) Cod liver oil,  provided that the product is labeled so that the amount                                                        |
| provided that | (3) Shark liver oil,  provided that the product is labeled so that the amount                                                      |
| when          | the product consists of any of the following when used within the concentration range established for each                         |
| when          | the product consists of any of the following when used within the concentration range established for each                         |
| when          | the product consists of any of the following when used within the concentration range established for each                         |
| provided that | (8) and (10), and (b) (2) and (3), provided that the combined percentage by weight of all protectants                              |
| if            | product contains the established name of the drug, if  any, and ident                                                              |
| subject to    | used, as provided in &#167;&#8201;330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal             |
| unless        | (2) &#8220;Do not exceed the recommended daily dosage unless directed by a doctor.&#8221; (3) &#8220;In case of                    |
| if            | &#8220;Do not use this product with an applicator  if the introduction of the applicator into the rectum                           |
| if            | the symptom being treated does not subside or if redness, irritation, swelling, pain, or other symptoms develop                    |
| if            | (i) &#8220;Do not use this product  if you have heart disease, high blood pressure, thyroid                                        |
| unless        | urination due to enlargement of the prostate gland unless directed by a doctor.&#8221; (ii) &#8220;Ask a doctor                    |
| if            | (i) &#8220;Do not use this product  if you have heart disease, high blood pressure, thyroid                                        |
| when          | patting or blotting with an appropriate cleansing pad&#8221;). when                                                                |


## Entities

| Entities        | Context                                                                                                                    |
|:----------------|:---------------------------------------------------------------------------------------------------------------------------|
| Food            | Food  and Drugs.                                                                                                           |
| Scope           | Scope .                                                                                                                    |
| Topical         | Topical application of an anorectal drug product to the                                                                    |
| Topical         | Topical application of an anorectal drug product to the                                                                    |
| Local           | Local  anesthetic active ingredients.                                                                                      |
| Vasoconstrictor | Vasoconstrictor  active ingredients.                                                                                       |
| Analgesic       | Analgesic , anesthetic, and antipruritic active ingredients.                                                               |
| Calamine        | the concentration range established for each ingredient: (a) Calamine , within a concentration range of 5 to               |
| Witch           | (b)  Witch  hazel, 10 to 50 percent.                                                                                       |
| Keratolytic     | Keratolytic  active ingredients.                                                                                           |
| Permitted       | Permitted  combinations of anorectal active ingredients.                                                                   |
| Indications     | of the product states, under the heading &#8220; Indications ,&#8221; any of the phrases listed in paragraph               |
| Temporarily     | (A) &#8220; Temporarily reduces the swelling associated with&#8221; (select one of                                         |
| Temporarily     | (B) &#8220; Temporarily shrinks hemorrhoidal tissue.&#8221; (iii) For products for external                                |
| Temporarily     | (A) &#8220; Temporarily forms a protective coating over inflamed tissues to                                                |
| Temporarily     | (A) &#8220; Temporarily forms a protective coating over inflamed tissues to                                                |
| Temporarily     | (A) &#8220; Temporarily forms a protective coating over inflamed tissues to                                                |
| Temporarily     | (A) &#8220; Temporarily forms a protective coating over inflamed tissues to                                                |
| Temporarily     | (G) &#8220; Temporarily  protects inflamed perianal skin.&#8221;                                                           |
|                 |               (H) &#8220;                                                                                                  |
| Temporarily     | (G) &#8220; Temporarily  protects inflamed perianal skin.&#8221;                                                           |
|                 |               (H) &#8220;                                                                                                  |
| Can             | (B) &#8220; Can help distract from pain.&#8221; (C) &#8220;May provide a                                                   |
| Certain         | &#8220; Certain persons can develop allergic reactions to ingredients in                                                   |
| Remove          | &#8220; Remove petrolatum or greasy ointment before using this product                                                     |
| Children        | &#8220; Children under 12 years of age: consult a doctor.&#8221;                                                           |
| Remove          | &#8220; Remove wrapper before inserting into the rectum.&#8221; (5) For                                                    |
| Lubricate       | Lubricate applicator well, then gently insert applicator into the                                                          |
| Apply           | Apply to the affected area up to 6 times                                                                                   |
| Apply           | Apply to the affected area up to 3 or                                                                                      |
| Apply           | Apply to the affected area up to 5 times                                                                                   |
| Apply           | Apply to the affected area up to 4 times                                                                                   |
| Apply           | Apply to the affected area up to 6 times                                                                                   |
| Apply           | Apply liberally to the affected area as often as                                                                           |
| Indications     | Indications , warnings, and directions for use, respectively, applicable                                                   |
| Indications     | of the product states, under the heading &#8220; Indications ,&#8221; the indication(s) for each ingredient in the         |
| Warnings        | of the product states, under the heading &#8220; Warnings ,&#8221; the warning(s) for each ingredient in the               |
| Directions      | of the product states, under the heading &#8220; Directions ,&#8221; directions that conform to the directions established |


## Date

| Date       | Context                                                                                                                                                                                                                                      |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-01-20 | (3) Glycerin in a 20- to 45-percent (weight/weight) aqueous solution so that the final product contains not less than 10 and not more than 45 percent glycerin (weight/weight).                                                              |
| 2018-05-20 | (b) Any single anorectal ingredient identified in &#167;&#8201;346.10, 346.12, 346.16, 346.18, or 346.20 may be combined with up to four protectants in accordance with paragraph (a) of this section.                                       |
| 2018-05-10 | (c) Any single local anesthetic identified in &#167;&#8201;346.10 may be combined with any single vasoconstrictor identified in &#167;&#8201;346.12.                                                                                         |
| 2018-05-10 | (d) Any single local anesthetic identified in &#167;&#8201;346.10 may be combined with any single astringent identified in &#167;&#8201;346.18.                                                                                              |
| 2018-05-10 | (e) Any single local anesthetic identified in &#167;&#8201;346.10 may be combined with any single keratolytic identified in &#167;&#8201;346.20.                                                                                             |
| 2018-05-12 | (f) Any single vasoconstrictor identified in &#167;&#8201;346.12 may be combined with any single astringent identified in &#167;&#8201;346.18.                                                                                               |
| 2018-05-16 | (g) Any single analgesic, anesthetic, and antipruritic identified in &#167;&#8201;346.16 may be combined with any single astringent identified in &#167;&#8201;346.18.                                                                       |
| 2018-05-16 | (h) Any single analgesic, anesthetic, and antipruritic identified in &#167;&#8201;346.16 may be combined with any single keratolytic identified in &#167;&#8201;346.20.                                                                      |
| 2018-05-18 | (i) Any single astringent identified in &#167;&#8201;346.18 may be combined with any single keratolytic identified in &#167;&#8201;346.20.                                                                                                   |
| 2018-05-10 | (j) Any single local anesthetic identified in &#167;&#8201;346.10 may be combined with any single vasoconstrictor identified in &#167;&#8201;346.12 and with any single astringent identified in &#167;&#8201;346.18.                        |
| 2018-05-10 | (k) Any single local anesthetic identified in &#167;&#8201;346.10 may be combined with any single astringent identified in &#167;&#8201;346.18 and with any single keratolytic identified in &#167;&#8201;346.20.                            |
| 2018-05-12 | (l) Any single vasoconstrictor identified in &#167;&#8201;346.12 may be combined with any single analgesic, anesthetic, and antipruritic identified in &#167;&#8201;346.16 and with any single astringent identified in &#167;&#8201;346.18. |
| 2018-05-16 | (m) Any single analgesic, anesthetic, and antipruritic identified in &#167;&#8201;346.16 may be combined with any single astringent identified in &#167;&#8201;346.18 and with any single keratolytic identified in &#167;&#8201;346.20.     |


